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Abstract Purpose: Accurate early
anticipation of long-term irreversible
brain damage during the acute phase
of patients with aneurysmal sub-
arachnoid hemorrhage (aSAH)
remains difficult. Using a combina-
tion of clinical scores together with
brain injury-related biomarkers
(H-FABP, NDKA, UFD1 and
S100b), this study aimed at develop-
ing a multiparameter prognostic panel
to facilitate early outcome prediction
following aSAH. Methods: Blood
samples of 141 aSAH patients from
two separated cohorts (sets of 28 and
113 patients) were prospectively
enrolled and analyzed with
14 months of delay. Patients were
admitted within 48 h following aSAH
onset. A venous blood sample was
withdrawn within 12 h after admis-
sion. H-FABP, NDKA, UFD1, S100b
and troponin I levels were determined
using classical immunoassays. The
World Federation of Neurological
Surgeons (WFNS) at admission and
the Glasgow Outcome Score (GOS)
at 6 months were evaluated.
Results: In the two cohorts, blood
concentration of H-FABP, S100b and
troponin I at admission significantly
predicted unfavorable outcome (GOS
1–2–3). A multivariate analysis
identified a six-parameter panel,
including WFNS, H-FABP, S100b,
troponin I, NDKA and UFD-1; when
at least three of these parameters were
simultaneously above cutoff values,
prediction of unfavorable outcome
reached around 70% sensitivity in
both cohorts for 100% specificity.
Conclusion: The use of this panel,
including four brain injury-related
proteins, one cardiac marker and a
clinical score, could be a valuable
tool to identify aSAH patients at risk
of poor outcome.
Keywords Aneurysmal
subarachnoid hemorrhage  H-FABP 
NDKA  S100b  Prognosis
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Introduction
Besides the high early mortality associated with aSAH,
long-term neurological morbidity is also a significant
problem in a substantial proportion of these patients [1,
2]. Identification of prognostic factors, aimed to predict
patient outcome, would help in the management and
decision making within this population. Clinical scores,
such as WFNS classification, demonstrated an associa-
tion between prognosis following aSAH and the
patient’s clinical neurological status at hospital admis-
sion [3]. Biochemical markers may provide additional
information about specific pathological disruptions and
recovery processes that occur in the central nervous
system following aSAH. In conjunction with clinical
status, these biomarkers may also inform prognosis and
guide therapeutic decisions to optimize treatments
[4, 5].
Over the past few years, a large number of biomarkers,
present in the blood and CSF, have raised interest in the
detection of aSAH patients with poor clinical outcome.
Nevertheless, the majority of these markers displayed
either low sensitivity or specificity to anticipate the
detection of patients with poor outcome [6, 7].
We recently explored post-mortem CSF as a model of
massive brain insult [8, 9]. In these studies, heart-fatty
acid binding protein (H-FABP), nucleotide diphosphate
kinase A (NDKA) and ubiquitin fusion degradation pro-
tein 1 (UFD-1) were over-expressed in post-mortem
compared to ante-mortem CSF and were validated as
potential brain damaged biomarkers [10–12]. In the
present study, we hypothesized that such a reliable plas-
matic marker may provide quantitative information
reflecting the prediction of aSAH patient outcome. The
objective of this study was to determine, immediately at
the hospital admission, S100b, H-FABP, troponin I,
NDKA and UFD-1 protein blood concentrations of
patients with spontaneous aSAH obtained in two sepa-
rated cohorts from the same institution. In addition to
specific clinical parameters, their potential predictive




The inclusion period was from July 2004 to December
2006 in the Pitie´-Salpeˆtrie`re Hospital (Paris, France).
Inclusion criteria were clinical history of aSAH within the
last 2 days before admission with evidence of bleeding in
CT and presence of an aneurysm at cerebral angiography,
age above 18 years old and treatment by surgery or
coiling within 48 h after admission. Each eligible patient
was admitted in the intensive care unit (ICU) within the
2 days after aSAH symptom onset (mean 7 ± 18 h, min
3 h and max 48 h), and a unique venous blood sample
was withdrawn within 12 h after ICU admission (mean
24 ± 13.9 h). Fifty-nine patients were excluded due to
either a delay of more than 48 h after the onset of
symptoms (n = 55) or missing clinical information
(n = 3). A total of 199 consecutive patients were evalu-
ated, and 141 were finally enrolled in this study.
Samples were sent from Paris to Geneva in two
distinct sets of samples with a 14-month period delay.
As samples were analyzed immediately in Geneva,
results between the two sets displayed a 14-month
period delay explaining why the two sets were con-
sidered separately. The selection set had 28 patients (8
men and 20 women; age range 26–84 years) and the
verification set 113 patients (42 men and 71 women;
age range 18–81 years). Fifty patients (35.4% of the
study sample) had an unfavorable outcome at 6 months
(GOS score 1–3), and 91 (65%) patients had a favor-
able outcome (GOS score 4–5). The two sets are
described in Table 1.
The local ethical committee (Comite´ de Protection des
Personnes, Pitie´-Salpeˆtrie`re, Paris, France) approved the
study. In accordance with the Helsinki Declaration,
written informed consent was obtained from the patient or
patient’s relatives.
Clinical monitoring and treatment
At admission, clinical severity was assessed using the
WFNS score [16]. The initial CT was reviewed by an
independent radiologist blinded to clinical history and
classified according to the original Fisher score [17]
modified as follows: grade 1, no subarachnoid blood;
grade 2, broad diffusion of subarachnoid blood; grade 3,
with clots or thick layers of blood; grade 4, intraventric-
ular hemorrhage or intracerebral hematoma, no clot;
grade 5, intraventricular hemorrhage or intracerebral
hematoma with clot [18–20] and qualified presence or
absence of acute hydrocephalus. The neurological out-
come was assessed by phone interviews using the
Glasgow Outcome Scale (GOS) [21] at 6 months. The
type of treatment (surgery or coiling) was decided
according to both location and size of the aneurysm by the
neurosurgeon and the neuro-radiologist. Seizures were
routinely prevented by gabapentin (600 mg t.i.d., per os).
A central venous line and an arterial catheter were
inserted in most of the patients before and/or after surgery
or coiling. An external ventricular drain (Sophysa, Orsay,
France) was inserted in patients with CT evidence of
hydrocephalus, high WFNS grade or a trans-cranial
Doppler (TCD) pulsatility index greater than 1.2, sug-
gesting intracranial pressure (ICP) elevation. The line was
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connected to an external pressure strain gauge to monitor
ICP. Early ICP elevation was defined as ICP above
20 mmHg under sedation but without drainage. Moni-
toring and treatment of vasospasm are described in Online
Data Supplement 1.
H-FABP, S100b, NDKA, UFD1 and troponin I
measurements
Cardiac troponin I serum concentration was systemati-
cally measured using the Stratus Analyzer (Dade, Massy,
France). S100b concentration was measured with an im-
munoluminometric sandwich assay on a LIA-mat 300
analyzer (Byk-Sangtec France Laboratories, Le Me´e sur
Seine, France) using the manufacturer’s reagents [22].
H-FABP concentration was determined with a commer-
cially available enzyme-linked immunosorbent assay
(ELISA) (Hycult Biotechnology, Uden, The Netherlands)
according to the manufacturer’s instructions. The
concentrations of NDKA and UFD1 were determined by
home-made ELISA as previously described by Allard
et al. [11, 12]. For more details, see the Online Data
Supplement 2.
Data analysis and statistics
SPSS software (version 15, SPSS Inc., Chicago, IL), R
(URL http://www.R-project.org) and PERL (ActivePerl
version 5.8.8.820, ActiveState Software Inc.) were used
for data analysis.
Because protein concentrations did not show normal
distributions (Kolmogorov–Smirnov test), between-group
differences were tested with the non-parametric Mann–
Whitney U test. The Fisher exact test was used for cate-
gorical variables. Statistical significance was set at 0.05
(two-tailed tests).
The dichotomized 6-month GOS score was considered
as the main outcome variable, with ranges 1–2–3 and 4–5
reflecting unfavorable and favorable outcome, respectively.
Table 1 Main characteristics of the population











# n% 3 (33.3) 5 (26.3) 20 (48.8) 22(30.6)
$ n% 6 (66.4) 14 (73.7) 21(51.2) 50(69.4)
Age (years) 0.86 0.043
Median (range) 56 (49–75) 57 (26–84) 55.0 (31–81) 49.5 (18–76)
Mean (±SD) 56.9 (±7.4) 53.5 (±14.1) 54.9 (±13.3) 48.9 (±13.8)
Time of blood drawing (h) 0.74 0.73
Median (range) 24 (6–24) 22.5 (11–48) 24 (10–48) 24 (5–48)
Mean (±SD) 20.4 (±6.3) 22.9 (±11.8) 21.8 (±10.5) 20.9 (±9.9)
WFNS score 0.026 \0.0001
1–2 n% 4 (44.4) 18 (94.8) 14 (34.1) 57 (79.2)
3–4–5 n% 5 (55.6) 1 (5.2) 27 (67.5) 15 (20.8)
Modified Fisher score 0.14 \0.0001
1–2 n% 0 (0.0) 5 (26.3) 0 (0.0) 19 (26.4)
3–4–5 n% 9 (100.0) 14 (73.8) 41 (100.0) 53 (73.6)
Vasospasm 0.08 0.48
No n% 6 (66.7) 18 (94.8) 27 (65.9) 54 (75.0)
Yes n% 3 (33.3) 1 (5.2) 14 (34.1) 19 (25.0)
Location 0.23 0.32
MCA n% 3 (33.3) 1 (5.2) 12 (29.3) 11 (15.3)
CA n% 3 (33.3) 10 (52.7) 19 (46.3) 36 (50.0)
ICA/PCA n% 3 (33.3) 7 (36.9) 10 (24.4) 23 (31.9)
VBS n% 0 1 (5.2) 0 (0.0) 2 (2.8)
Treatment 0.12 0.29
No n% 1 (11.1) 0 2 (4.9) 2 (2.8)
Coiling n% 6 (66.7) 18 (94.8) 29 (70.7) 60 (83.3)
Surgery n% 2 (22.2) 1 (5.2) 10 (24.4) 10 (13.9)
Seizures 1 0.89
No n% 6 (66.7) 13 (68.4) 33 (80.5) 58 (80.0)
Yes n% 3 (33.3) 6 (31.6) 8 (19.5) 14 (19.4)
Age non-parametric Mann–Whitney U test
MCA middle cerebral artery, CA cerebral anterior artery, ICA internal carotid artery, PCA posterior communicating artery, VBS vertebro
basilar system
a Fisher exact test
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The different markers (H-FABP, S100b, troponin I,
NDKA, UFD-1) as well as clinical data were considered
as possible predictors.
For each individual predictor, a receiver-operating
characteristic (ROC) curve was determined in each
cohort, and a cutoff value was selected as the threshold
predicting poor outcome with specificity [90%. Partial
ROC AUCs (pAUC) [23, 24] and 95% confidence inter-
vals (CI) were calculated using an adaptation of
previously described algorithms [25]. pAUCs were
restricted between 90 and 100% specificity considering
that an efficient predictor in clinical practice should be
able to identify clearly at least nine out of ten patients as
having a favorable prognosis when the test was negative.
P values for the difference between two pAUCs were
computed based on [26] where standard deviation was
determined by bootstrap as described above.
Univariate and multivariate logistic regressions with
stepwise backward selection were performed using SPSS
software and are described in Online Data Supplements 3
and 4, respectively.
Panel development
Panel selection was performed essentially as described by
Reynolds et al. [27, 28]. Briefly, the optimized cutoff
values were obtained by iterative permutation-response
calculations using all available parameters. Each cutoff
value was changed iteratively by quantiles of 2% incre-
ment, and sensitivity was determined after each iteration
until a maximum of sensitivity was achieved for 100%
specificity. Binary clinical parameters (hydrocephaly,
vasospasm, sex and statin treatment) were recorded as 0/1
(absent/present), and a unique cutoff of 0.5 was used.
Results
Patients with favorable and unfavorable outcomes did not
significantly differ with respect to gender. Age of patients
with poor outcome at 6 months was slightly higher in the
113-patient set, suggesting that age might be considered as
a prognostic factor. WNFS score was significantly higher in
patients with a poor outcome than favorable outcome
(Fisher’s exact test, P = 0.026 and\0.0001 in the 28- and
113-patient sets, respectively). A modified Fisher score,
estimating severity of aSAH, did not significantly differ
according to outcome in the 28-patient set, whereas in the
113-patient set, severe aSAH (high modified Fisher score)
was significantly associated with unfavorable outcome
(Fisher’s exact test, P \ 0.0001). No associations were
found between long-term neurological outcome and time
course of blood samples drawings, post-hemorrhagic sei-
zures, location of the aneurysm, occurrence of vasospasm
and treatment modality (coiling vs. surgery). Demographic
characteristics are shown in Table 1.
As shown in Table 2, baseline H-FABP, S100b and
troponin I levels were significantly elevated in the blood
of patients with an unfavorable outcome compared to
patients with a favorable outcome. Initial NDKA and
UFD-1 levels were unable to discriminate between
favorable and unfavorable outcome in the 28-patient set,
but in the 113-patient set, the NDKA level was marginally
higher in patients with a poor 6-month outcome
Table 2 H-FABP, S100b, troponin I, NDKA and UFD-1 concentrations (lg/l) at admission according to the patient outcome at 6 months
in the 28- and 113-patient sets











Median (range) 4.65 (1.73–62.2) 1.79 (0.86–9.03) 0.01 3.59 (0.63–67.36) 1.35 (0–44.43) \0.0001
Mean (±SD) 12.06 (±19.16) 2.82 (±2.13) 10.33 (±16.30) 3.50 (±7.33)
S100b (lg/l)
Median (range) 0.33 (0.17–0.46) 0.15 (0.06–0.32) 0.04 0.30 (0.03–2.07) 0.11 (0.04–0.5) \0.0001
Mean (±SD) 0.32 (±0.14) 0.163 (±0.84) 0.39 (±0.37) 0.16 (±0.13)
Troponin I (lg/l)
Median (range) 0.50 (0.04–6.4) 0.05 (0.04–2.62) 0.04 0.36 (0.03–155) 0.05 (0.03–4.4) \0.0001
Mean (±SD) 1.92 (±2.54) 1.15 (±3.18) 5.51 (±24.2) 0.32 (±0.77)
NDKA (lg/l)
Median (range) 13.74 (0–46.39) 13.98 (2.31–32.81) 0.92 13.56 (3.9–419.2) 10.95 (3.0–80.3) 0.05
Mean (±SD) 15.6 (±13.76) 15.9 (±10.45) 28.08 (±64.2) 14.86 (±12.8)
UFD-1 (lg/l)
Median (range) 71.0 (1.83–24.55) 12.6 (0.39–33.8) 0.33 83.73 (3.61–1792) 84.48 (10.4–553.2) 0.99
Mean (±SD) 11.23 (±8.14) 15.06 (±10.21) 169.3 (±291.6) 108.3 (±87.9)
P = Non-parametric Mann–Whitney U test. P \ 0.05 is considered significant
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(P = 0.073, Mann–Whitney U test). No significant dif-
ference was observed in the molecule concentrations as a
function of time of blood drawing (data not shown).
The prediction performances of individual molecules,
neurological scales and age for predicting a poor outcome
were evaluated with ROC curves and pAUC (Fig. 1).
Thresholds of individual predictors were chosen to pro-
vide specificity above 90% except for WFNS and
modified Fisher where the cutoff value was fixed to sep-
arate patients according to their clinical pattern. With a
threshold strictly above 2, WFNS allowed to discriminate
patients with poor and favorable outcome with 55.6%
sensitivity (SE) and 97.4% specificity (SP) in the
28-patient set and 67.5% SE for 79.2% SP in the
113-patient set. The modified Fisher scale (threshold[2)
provided perfect 100% sensitivity in the two sample sets
but low specificity (26.4 vs. 29.0%).
In the 28-patient set, H-FABP, S100b and troponin I
displayed 44.4, 33.0 and 22.2% SE for 94.7, 94.0 and
94.7% SP, respectively. Similar performances were
obtained in the 113-patient set. NDKA, UFD1 and age led
to relatively poor prediction of outcome at 6 months in the
two sets (Tables 3, 4). Univariate and multivariate logistic
regressions with stepwise backward selection were used to




























































































































































Fig. 1 pAUC of the different
parameters on the selection
(N = 28) and verification
(N = 113) sets. Grey boxes
correspond to the maximal area
(10%) between 90 and 100%
SP if a perfect ROC curve was
obtained. Dark boxes
correspond to the partial area
under the curve
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validate predictors of poor outcome. Results are presented
in Online Data Supplements 3 and 4, respectively.
Provided the low sensitivity obtained with individual
predictors, we tested combinations of all parameters on
the 28-patient set to select a panel that could improve
outcome prediction. The iterative permutation-response
approach led to a six-parameter panel including WFNS,
H-FABP, S100b, troponin I, NDKA and UFD-1. The
panel result was defined as positive if at least three out of
the six selected parameters were simultaneously above
threshold with 77% (95% CI: 50.0–100.0%) SE for 100%
(95% CI: 100.0–100.0) SP. This panel tested on the 113-
patient set presented extremely similar performances with
68.3% (95% CI: 53.5–82.2) SE for 100% (95% CI:
100.0–100.0) SP. The panel was confirmed by a ten-fold
cross-validation (data not shown). The six-parameter
panel allowed to increase sensitivity by about 25% when
compared to the best single predictor (H-FABP,
SE: 45%). In addition, pAUC of the panel was signifi-
cantly higher than pAUC of WFNS (P \ 0.0002). The
relative performance of each marker was also evaluated
by removing them one by one from the panel and
recalculating sensitivity and specificity. The results
obtained are shown in Online Data Supplement 5.
Importantly including both clinical and laboratory vari-
ables into the same panel was found to be superior to
approaches combining either purely clinical or merely lab-
oratory variables. Indeed, a clinical panel including WFNS,
modified Fisher scale and age displayed only 22% SE for
100% SP to predict poor outcome in the 113-patient set. The
presence of hydrocephaly and occurrence of vasospasm in
the clinical panel did not improve the discriminating per-
formance of the clinical panel. In line with this, a panel
containing only the five laboratory variables reached only
50% SE for 100% SP (Fig. 1). pAUC of our panel was sig-
nificantly higher than pAUC of both purely clinical and
laboratory panels (P = 0.0004 and 0.05, respectively.)
Discussion
In this prospective study, including 141 patients from two
separated cohorts of patients presenting aSAH, we have









WFNS 3.0% (0.0–8.2) [2a 55.6 (20.0–88.9) 94.1 (81.3–100)
Modified Fisher 1.7% (0.0–3.8) [2a 100 (100–100) 29.4 (8.3–52.9)
Age 1.1% (0.0–3.6) 72.5 years old 11.1 (0.0–33.3) 100 (100–100)
H-FABP 5.1% (1.7–8.8) 6.3 lg/l 44.4 (12.5–80.0) 100 (100–100)
S100b 2.0% (0.0–6.7) 0.37 lg/l 33.3 (0.0–66.7) 94.1 (80.0–100)
Troponin I 0.9% (0.0–6.7) 5.3 lg/l 22.2 (0.0–50.0) 94.1 (80.0–100)
NDKA 1.1% (0.0–3.8) 31.9 lg/l 11.1 (0–37.5) 100 (100–100)
UFD-1 0.0% (0.0–1.4) 24.87 lg/l 0 (0–0) 76.5 (53.8–94.4)
a A threshlod strictly above two for the neurological scores means that patients have been dichotomized into two groups: patients with
WFNS 1–2 and patients with WFNS 3–5 or patients with modified Fisher 1–2 and patients with modified Fisher 3–5









WFNS 3.3% (1.7–5.4) [2a 65.9 (51.1–79.2) 79.1 (69.6–88.1)
Modified Fisher 2.1% (0.9–3.6) [2a 100 (100–100) 26.4 (16.7–36.8)
Age 1.5% (0.6–2.6) 67.5 years old 20.4 (9.5–32.6) 92.0 (86.0–97.4)
H-FABP 1.9% (0.5–4.0) 5.9 lg/l 41.4 (26.5–56.8) 91.7 (84.7–97.3)
S100b 3.3% (1.9–4.9) 0.48 lg/l 31.7 (17.8–46.5) 97.2 (92.9–100)
Troponin I 2.5% (1.2–4.3) 1.56 lg/l 29.3 (15.6–43.9) 93.1 (86.8–98.6)
NDKA 1.0% (0.2–2.5) 30.4 lg/l 19.5 (8.3–32.4) 93.1 (86.5–98.6)
UFD-1 1.7% (0.6–3.0) 271.5 lg/l 19.5 (7.9–32.5) 97.2 (93.0– 100)
a A threshlod strictly above two for the neurological scores means that patients have been dichotomized in two groups: patients with
WFNS 1–2 and patients with WFNS 3–5 or patients with modified Fisher 1–2 and patients with modified Fisher 3–5
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demonstrated for the first time that elevated serum con-
centration of H-FABP at hospital admission was able to
predict unfavorable clinical prognosis at 6 months. More
importantly, the development of a multiparameter panel
strategy, using a combination of blood-borne biomarkers
together with a clinical score (WFNS), considerably
improved unfavorable outcome prediction compared to
solely clinical parameters, alone or in combination, by
allowing identification of poor neurological outcome in
patients with a sensitivity around 70% and a specificity of
100% following aSAH.
Identification of predictors is an important aspect of
the management and study of patients with aSAH. Several
clinical factors have been identified as independent pre-
dictors of patient outcome following aSAH [3, 29, 30].
Among them, clinical scores describing the patient’s
neurological condition at hospital admission were repor-
ted to correlate with long-term outcome [31, 32]. In line
with these observations, we also showed that, when tested
individually, the WFNS score at hospital admission
appeared to be the strongest predictor of neurological
outcome in our patient sample. In agreement with previ-
ous studies [17, 33], we found a significant correlation
between the amount of blood observed in the initial CT
scan and long-term neurological outcome. Although the
majority of earlier studies designed age as a major inde-
pendent prognostic factor [34, 35], a recent, prospectively
conducted trial including 177 poor WFNS grade patients
with aSAH did not find a significant association between
age and outcome [36]. In our cohort, the age of patients
presenting a poor GOS at 6 months was slightly but sig-
nificantly higher than those with a favorable course,
suggesting a potential influence of age as a prognostic
factor. In contrast, we found no significant association
between occurrence of vasospasm and seizure activity
during hospital stay and long-term GOS outcome. Also,
neither the aneurysm location site nor the treatment
modality (i.e., clipping versus coiling) showed significant
association with patient prognosis.
To our knowledge, this is the first study investigating
the role of the recently identified, brain-related biomark-
ers H-FABP, NDKA and UFD-1 in the context of aSAH.
These molecules have recently been shown to be reliable
early blood biomarkers in ischemic stroke. H-FABP is a
well-known marker for myocardial injury [37, 38] and
also appears to be a potential biomarker of stroke [10, 39].
Results of the present study revealed that H-FABP was
one of the best outcome predictors at 6 months (42.5% SE
and 92% SP), and its performance was as high as WFNS.
In addition, H-FABP was an important parameter of the
panel, since its absence induces a decrease of the sensi-
tivity from 70 to 47%.
NDKA (also called NM23-H1) is an ubiquitous
enzyme that catalyzes the transfer of the terminal phos-
phate of ATP to (deoxy)nucleotide triphosphates via the
formation of a high-energy phosphorylated intermediate.
Specific expression pattern and enzymatic activity of this
protein have been demonstrated in the brain [40]. In
stroke, NDKA was described as an early biomarker since
its level was already elevated in blood of patients within
3 h after the stroke onset [11]. In the present aSAH study,
NDKA alone appeared to be an unsatisfactory predictor of
outcome at 6 months. However, in combination with other
parameters, its presence drastically increased the sensi-
tivity of the panel, suggesting that its strength resides in
the detection of patients not included by other predictors.
Several studies highlighted an increasing interest in
S100b, a calcium-binding protein, in various brain damage
disorders, and especially in aSAH [6, 41]. In these studies,
elevated levels of S100b correlated with neurological
deficit and outcome at 6 months or 1 year [18–20]. Our
present results are in line with these observations, showing
a 35% SE and 96% SP of this protein in the prediction of
neurological outcome at 6 months.
The commonly used cardiac biomarker troponin I, also
known as cardiac isoform of troponin I (cTnI), has pre-
viously been reported to be correlated with neurological
outcome following aSAH [42]. In fact, cardiopulmonary
dysfunctions could occur after aSAH, but their impacts
in the mortality rate or outcome remain controversial
[43, 44]. In our study, troponin I permitted to discriminate
patients according to their outcome with 30% SE and
93% SP, and, in combination with other markers, it
increased the sensitivity of the panel from 42 to 70%.
Outcome prediction based on a single measured bio-
marker or clinical score has led so far to unsatisfactory
levels of sensitivity and, more importantly, specificity.
Therefore, there is an urgent need to combine multiple
parameters to achieve higher sensitivity without sacrificing
specificity. Many studies have evaluated a multitude of
classification approaches to improve the prediction per-
formance [45]. In the present study, we used a
multiparametric combination of blood-borne protein val-
ues and clinical scores. The iterative permutation-response
highlighted that a six-parameter panel comprising WFNS,
H-FABP, S100b, troponin I, NDKA and UFD-1 could be
used for the prediction of aSAH outcome at 6 months. The
six-parameter panel provided increasing prognosis sensi-
tivity (70%) for 100% SP compared with any other
parameter individually or purely clinical and laboratory
panels (22% and 50% SE, respectively), when at least three
out of the six predictors are above their cutoff values.
The future challenge for these biomarkers and panel is
their translation in clinical practice. Several drawbacks
must be solved to consider their real prospective impact in
the management of SAH patients. Among them, the
development of multiplex point-of-care systems should
considerably reduce the time of analyses (between 15 and
30 min), making possible their use in routine clinical
practice. Alternatively, new emerging ELISA technolo-
gies, such as bead suspension arrays, can also quantitate
simultaneously several biomarkers in a unique patient
113
sample, restricting the volume need for analyses, and this
in a fast and reproducible manner. Finally, the panel
interpretation (binary response: positive or negative) is
simple enough to be used in clinical practice.
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